Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

European Innovation Council · Running

3DPATH Enabling the transition to 3D digital pathology

Coordinator
Clepio Biotech SRL, Italy
Runs
1 April 2025 to 31 March 2028
Status
Running
EU funding
€2.5m
Total cost
—
Partners
3 organisations in 3 countries
Type
European Innovation Council
Grant agreement
101213930

What the project is doing

In the project's own words, from its summary on CORDIS.

Histopathology is a century-old standard for the diagnosis of cancer and other diseases, and for the choice of personalized treatments. Despite its paramount importance for clinical practice, this method is still limited to the analysis of thin slices, presenting a 2D view of the intrinsically 3D structure of biological tissue. Current histopathology practice poses the risk of severely undersampling relevant tissue features: indeed, a growing amount of data demonstrates that traditional 2D analysis produces inconsistent and unreliable results that may have important implications in treatment choice and other clinical decisions.

Despite the compelling evidence of the clinical benefits of volumetric tissue analysis, clinical practice is still anchored to 2D imaging. A transition towards 3D inspection would be a quantum leap in the histopathology field but has been prevented hitherto because of technical limitations. Indeed, light-sheet fluorescence microscopy (LSFM) has been hailed in the last decades as a game changer in the field. However, LSFM-based solutions have profound limitations in terms of throughput, reliability and scalability that prevent their use outside specialised research labs.

In 3DPATH, we want to leverage several key innovations in LSFM and data analysis technology – developed in previous research projects – to develop a 3D tissue scanner suitable for clinical use. The success of this project will revolutionize histopathology leading to more accurate diagnosis, improving quality of care for patients all over the world, and bringing Europe at the forefront of diagnostic technologies.

Topics

Who is involved

OrganisationCityCountryRole
Clepio Biotech SRLSesto FiorentinoItalyCoordinator
Acmit GmbHWiener NeustadtAustriaParticipant
Universitaet BernBernSwitzerlandAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI